Patient in the second dose group of IMM01 project continued to benefit

On April 15, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM01, the first Fc fusion protein drug targeting human CD47 in China, had completed the second dose group clinical trial study in the Hematology Hospital of Chinese Academy of Medical Sciences, and the patient continued to benefit.

In the second dose group, the patient with relapsed and refractory follicular lymphoma was found to have shrunk in routine examination during DLT observation, and the patient felt well. The target lesion SPD decreased from 985 square mm at the time of enrollment to 558 square mm at the time of DLT observation. The clinical evaluation was SD. Recently, it was reduced to 400 square millimeter, and the clinical evaluation was PR.

"We are very glad to learn that our IMM01 project can work at such a low dose and benefit patient. This may be closely related to our molecular design, because IMM01 does not bind to red blood cells at all, thus avoiding the" antigenic sink "caused by this. At the same time, due to the elimination of glycosylation, PK is improved and the drug bioavailability is high.". Dr. Tian Wenzhi, founder of ImmuneOnco company, is confident in the clinical trial of IMM01. "At present, we are carrying out the third dose of subjects to be enrolled. We hope to further improve the efficacy of the drug after increasing the dose, so as to benefit more patients. Therefore, we will work closely with clinical experts, CRO companies and patients to accelerate the clinical trial research of IMM01 and speed up the marketing of IMM01, so as to benefit all patients with relapsed and refractory cancer as soon as possible. ".